Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis
This study will evaluate long-term safety of etanercept with or without other DMARDs in children with polyarticular course or systemic juvenile rheumatoid arthritis (JRA) compared to a cohort of subjects with polyarticular or systemic JRA receiving methotrexate with or without other DMARDs.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis|
- Adverse event rates and severity [ Time Frame: 36 months of observation ] [ Designated as safety issue: Yes ]
- Growth data and Tanner scores [ Time Frame: 36 months of observation ] [ Designated as safety issue: Yes ]
|Study Start Date:||June 2000|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
Etanercept alone, etanercept plus methotrexate or other DMARDs